Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.

Literature DB >> 22828444

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.

G Ramsingh, P Westervelt, A F Cashen, G L Uy, K Stockerl-Goldstein, C N Abboud, N Bernabe, R Monahan, J F DiPersio, R Vij.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22828444 DOI： 10.1038/leu.2012.214

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Authors: Alison R Walker; Rebecca B Klisovic; Ramiro Garzon; Larry J Schaaf; Kristina Humphries; Steven M Devine; John C Byrd; Michael R Grever; Guido Marcucci; William Blum
Journal: Leuk Lymphoma Date: 2013-09-09

2. Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

Authors: G Visani; F Ferrara; F Di Raimondo; F Loscocco; G Sparaventi; S Paolini; F Fuligni; A Gazzola; M Rossi; M A Laginestra; M R Caraci; C Riccardi; M Rocchi; A Visani; S A Pileri; P P Piccaluga; A Isidori
Journal: Leukemia Date: 2014-01-20 Impact factor: 11.528

Review 3. Hypomethylating Agents as a Therapy for AML.

Authors: Claude Gardin; Hervé Dombret
Journal: Curr Hematol Malig Rep Date: 2017-02 Impact factor: 3.952

4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

Authors: Courtney D DiNardo; Naval Daver; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Marina Konopleva; Naveen Pemmaraju; Hui Yang; Sherry Pierce; William Wierda; Carlos Bueso-Ramos; Keyur P Patel; Jorge E Cortes; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal: Lancet Haematol Date: 2014-12-22 Impact factor: 18.959

5. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Authors: Bob Löwenberg; Thomas Pabst; Johan Maertens; Patrycja Gradowska; Bart J Biemond; Olivier Spertini; Edo Vellenga; Laimonas Griskevicius; Lidwine W Tick; Mojca Jongen-Lavrencic; Marinus van Marwijk Kooy; Marie-Christiane Vekemans; Walter J F M van der Velden; Berna Beverloo; Lucienne Michaux; Carlos Graux; Dries Deeren; Okke de Weerdt; Joost W J van Esser; Mario Bargetzi; Saskia K Klein; Alain Gadisseur; Peter E Westerweel; Hendrik Veelken; Michael Gregor; Tobias Silzle; Daniëlle van Lammeren-Venema; Ine Moors; Dimitri A Breems; Mels Hoogendoorn; Marie-Cecile J C Legdeur; Thomas Fischer; Juergen Kuball; Jan Cornelissen; Kimmo Porkka; Gunnar Juliusson; Peter Meyer; Martin Höglund; Bjorn T Gjertsen; Jeroen J W M Janssen; Gerwin Huls; Jakob Passweg; Jacqueline Cloos; Peter J M Valk; Catharina H M J van Elssen; Markus G Manz; Yngvar Floisand; Gert J Ossenkoppele
Journal: Blood Adv Date: 2021-02-23

Review 6. Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).

Authors: Kazusa Ishii; Austin J Barrett
Journal: Ther Adv Hematol Date: 2016-02

7. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Authors: Ronan T Swords; Steven Coutre; Michael B Maris; Joshua F Zeidner; James M Foran; Jose Cruz; Harry P Erba; Jesus G Berdeja; Wayne Tam; Saran Vardhanabhuti; Iwona Pawlikowska-Dobler; Hélène M Faessel; Ajeeta B Dash; Farhad Sedarati; Bruce J Dezube; Douglas V Faller; Michael R Savona
Journal: Blood Date: 2018-01-18 Impact factor: 22.113